A Novel Agent Effective against Clostridium difficile Infection

被引：13

作者：

Dvoskin, Sofya ^{[1
]}

Xu, Wei-Chu ^{[1
]}

Brown, Neal C. ^{[1
]}

Yanachkov, Ivan B. ^{[1
]}

Yanachkova, Milka ^{[1
]}

Wright, George E. ^{[1
]}

机构：

[1] GLSynthesis Inc, Worcester, MA 01605 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 03期

基金：

美国国家卫生研究院;

关键词：

DISEASE; VANCOMYCIN; METRONIDAZOLE; DIARRHEA;

D O I：

10.1128/AAC.06097-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

N-2-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E) is a synthetic purine that selectively inhibits the replication-specific DNA polymerase of Clostridium difficile. MorE-DCBG and its analogs strongly inhibited the growth of a wide variety of C. difficile strains. When administered orally in a hamster model of C. difficile-specific colitis, 362E was as effective as oral vancomycin, the current agent of choice for treating severe forms of the human disease.

引用

页码：1624 / 1626

页数：3

共 50 条

[1] Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
Zhanel, George G.
Walkty, Andrew J.
Karlowsky, James A.
[J]. CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2015, 26 (06): : 305 - 312
[2] Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection
Kufel, Wesley D.
Devanathan, Aaron S.
Marx, Ashley H.
Weber, David J.
Daniels, Lindsay M.
[J]. PHARMACOTHERAPY, 2017, 37 (10): : 1298 - 1308
[3] Novel Chimeric Protein Vaccines Against Clostridium difficile Infection
Wang, Shaohui
Wang, Yuanguo
Cai, Ying
Kelly, Ciaran P.
Sun, Xingmin
[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
[4] Bezlotoxumab - A New Agent for Clostridium difficile Infection
Bartlett, John G.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04): : 381 - 382
[5] The Search for Effective Treatment of Clostridium difficile Infection
DuPont, Herbert L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 473 - 475
[6] Time to act against Clostridium difficile infection
Allerberger, F.
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 : 1 - 1
[7] CADAZOLID Antibacterial agent Treatment of Clostridium difficile Infection
Kefauver, S. C.
[J]. DRUGS OF THE FUTURE, 2014, 39 (05) : 325 - 332
[8] Ridinilazole: a novel antimicrobial for Clostridium difficile infection
Cho, Jonathan C.
Crotty, Matthew P.
Pardo, Joe
[J]. ANNALS OF GASTROENTEROLOGY, 2019, 32 (02): : 134 - 140
[9] Novel Antimicrobials for the Treatment of Clostridium difficile infection
Petrosillo, Nicola
Granata, Guido
Cataldo, Maria Adriana
[J]. FRONTIERS IN MEDICINE, 2018, 5
[10] Ridinilazole: a novel therapy for Clostridium difficile infection
Vickers, Richard J.
Tillotson, Glenn
Goldstein, Ellie J. C.
Citron, Diane M.
Garey, Kevin W.
Wilcox, Mark H.
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (02) : 137 - 143

← 1 2 3 4 5 →